COVID-19NCT05950243
COVID-19 Disease & Vaccine Survey in Africa
An observational study of COVID-19 and Vaccine Hesitancy, run by Salem Anaesthesia Pain Clinic at 1 site in Canada.
Trial summary
The COVID-19 pandemic is a public health concern; for which the WHO recommends protective measures and vaccination. There is inadequate data on the impact of COVID-19 vaccination and control measures in Africa. Read more about this study
- Who is it for?
- Ages 9 to 99 yearsHealthy volunteers can take part
- Conditions the study is for
- COVID-19, Vaccine Hesitancy
- What is being tested?
- Questionnaire
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 1,000 participants
- Where
- 1 siteCanada
- Study dates
- 2 Jan 2021to 31 Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 9 to 99 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Urban population in selected sub-Saharan African town or city
Who may be able to join
- urban population in Africa
- people in sub-Saharan Africa town
Who cannot join
- rural population
- people outside sub-Saharan Africa
Trial locations and contacts
1 site in 1 country.
About this study
Official title: COVID-19 Disease & Vaccine Survey in Sub-Saharan Africa
The COVID-19 pandemic is a public health concern; for which the WHO recommends protective measures and vaccination. There is inadequate data on the impact of COVID-19 vaccination and control measures in Africa. This survey is collecting data about people's knowledge, attitude and compliance regarding COVID-19 disease and vaccines.
Read the detailed description
The coronavirus disease 2019 (COVID-19) pandemic remains a major public health concern. There is inadequate data on the epidemiology of COVID-19 in Africa. There are emerging COVID-19 variants with high transmissibility and morbidity. The World Health Organization (WHO) recommends protective measures and vaccination; for the control of COVID-19. There is inadequate data on the impact of COVID-19 vaccination and control measures in many nations in Africa.
This study is a survey of specific urban populations in sub-Saharan Africa. The anonymized survey is collecting data about people's knowledge and attitude regarding COVID-19 disease or control measures. The survey is also collecting data about people's knowledge, attitude and compliance regarding COVID-19 vaccines. The study uses a validated questionnaire to collect data. The study aims to inform and improve COVID-19 management or control in Africa.
- Conditions
- COVID-19, Vaccine Hesitancy
- Being tested
- Questionnaire
- Keywords
- COVID-19
- Medical subject headings
- COVID-19, Vaccination Hesitancy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QuestionnaireBehavioural
Questionnaire survey for data collection
| Study group | Role | What they receive |
|---|---|---|
| Urban population Africa | Urban population in sub-Saharan Africa Receives: Behavioral: Questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of people who know about COVID-19 prevention
Percentage of people who know about COVID-19 preventive measures
Measured: 6 months
Percentage of people who received COVID-19 vaccination
Percentage of people who received COVID-19 vaccination, 1st and 2nd doses
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jul 2023
- Study start2 Jan 2021
- Primary completion31 Dec 2023
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Salem Anaesthesia Pain Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Olu Bamgbade, MD,FRCPC, Principal investigator, Salem Anaesthesia Pain Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05950243
- Sponsor's protocol ID
- SalemAnes2021 COVID Africa
- Status last verified
- Jan 2025
- First submitted
- 16 Jul 2023
- Last updated
- 27 Jan 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- COVID-19 Disease & Vaccine Survey in Sub-Saharan Africa
- ClinicalTrials.gov ID
- NCT05950243
- Acronym / sponsor ID
- SalemAnes2021 COVID Africa
- Conditions
- COVID-19, Vaccine Hesitancy
- Keywords
- COVID-19
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,000 participants (actual)
- Lead sponsor
- Salem Anaesthesia Pain ClinicUniversity, hospital or other
- Study start
- 2 Jan 2021 (actual)
- Primary completion
- 31 Dec 2023 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 18 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The COVID-19 pandemic is a public health concern; for which the WHO recommends protective measures and vaccination. There is inadequate data on the impact of COVID-19 vaccination and control measures in Africa. This survey is collecting data about people's knowledge, attitude and compliance regarding COVID-19 disease and vaccines.
Detailed description
The coronavirus disease 2019 (COVID-19) pandemic remains a major public health concern. There is inadequate data on the epidemiology of COVID-19 in Africa. There are emerging COVID-19 variants with high transmissibility and morbidity. The World Health Organization (WHO) recommends protective measures and vaccination; for the control of COVID-19. There is inadequate data on the impact of COVID-19 vaccination and control measures in many nations in Africa.
This study is a survey of specific urban populations in sub-Saharan Africa. The anonymized survey is collecting data about people's knowledge and attitude regarding COVID-19 disease or control measures. The survey is also collecting data about people's knowledge, attitude and compliance regarding COVID-19 vaccines. The study uses a validated questionnaire to collect data. The study aims to inform and improve COVID-19 management or control in Africa.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Urban population Africa | – | Behavioral: QuestionnaireUrban population in sub-Saharan Africa |
Who may qualify
- Ages
- 9 to 99 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Urban population in selected sub-Saharan African town or city
Key inclusion criteria (2 listed)
- urban population in Africa
- people in sub-Saharan Africa town
Key exclusion criteria (2 listed)
- rural population
- people outside sub-Saharan Africa
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QuestionnaireQuestionnaire survey for data collection | Behavioural | Urban population Africa |
Primary outcome
Percentage of people who know about COVID-19 prevention
Time frame: 6 months
Percentage of people who know about COVID-19 preventive measures
Percentage of people who received COVID-19 vaccination
Time frame: 6 months
Percentage of people who received COVID-19 vaccination, 1st and 2nd doses
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jan 2025.
- Individual participant dataSharing planned: No
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Olu Bamgbade, MD,FRCPC principal investigator
Salem Anaesthesia Pain Clinic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19 and Vaccine Hesitancy, run by Salem Anaesthesia Pain Clinic at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of people who know about COVID-19 prevention (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jan 2025.